Heqet Therapeutics is pioneering the development of first-in-class compounds that leverage non-coding RNA to address significant unmet medical needs, particularly in the realm of cardiac health. Their innovative approach focuses on the upregulation of specific non-coding RNAs that target multiple biological pathways, including critical components of the Hippo signaling pathway. This pathway is essential for regulating cell growth and organ size, and Heqet's compounds specifically influence key factors such as TAO kinase 1 (TAOK1) and the E3 ubiquitin-ligase β-transducing repeat containing protein (β-TrCP), as well as the actin cytoskeleton regulatory protein cofilin-2. 

The scientific foundation of Heqet Therapeutics' technology is supported by various publications that highlight the potential of microRNA therapies in promoting cardiac regeneration. Research has demonstrated that certain microRNAs can induce cardiac repair mechanisms following myocardial infarction, showcasing the therapeutic promise of non-coding RNA in regenerative medicine. By targeting these pathways, Heqet Therapeutics aims to create effective treatments that can significantly improve outcomes for patients with heart disease, marking a transformative shift in therapeutic strategies for cardiac conditions.

Italy

Heqet Therapeutics is a company that develops groundbreaking genetic medicines to reverse the damage of ischemic heart disease, the leading cause of death worldwide. Their therapeutic approach aims to address the underlying drivers of heart disease.

Heqet Therapeutics

Company Details